Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB Alliance's Pretomanid Seems OK Heading To Advisory Cmte. As US FDA Showcases Regulatory Flexibility

Executive Summary

The Global Alliance for TB Drug Development is seeking an approval for pretomanid as part of an oral combination regimen for highly resistant tuberculosis. 

You may also be interested in...



Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.

Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Achaogen can take solace in US FDA's approval of the aminoglycoside antibacterial for the treatment of complicated urinary tract infections, but the limited use indication for bloodstream infections was rejected. 

FDA's Yim Wants US To Emulate Europe On Biosimilars

In an exclusive interview with Generics Bulletin sister publication the Pink Sheet, the now-permanent OTBB director Sarah Yim discussed her expectations for the future of the US biosimilars market, her learning experience as acting director and upcoming challenges for her office.

Topics

Related Companies

UsernamePublicRestriction

Register

PS125412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel